2-Methoxycinnamaldehyde inhibits the TNF-α-induced proliferation and migration of human aortic smooth muscle cells

YOUNG-HEE JIN and SOO-A KIM

Department of Biochemistry, Dongguk University College of Oriental Medicine, Gyeongju 780-714, Republic of Korea

Received March 23, 2016; Accepted November 24, 2016

DOI: 10.3892/ijmm.2016.2818

Abstract. The abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) is a crucial event in the development of atherosclerosis, and tumor necrosis factor-α (TNF-α) is actively involved in this process by enhancing the proliferation and migration of VSMCs. 2-Methoxycinnamaldehyde (MCA) is a natural compound of Cinnamomum cassia. Although 2-hydroxycinnamaldehyde (HCA), another compound from Cinnamomum cassia, has been widely studied with regard to its antitumor activity, MCA has not attracted researchers’ interest due to its mild toxic effects on cancer cells and its mechanisms of action remain unknown. In this study, we examined the effects of MCA on the TNF-α-induced proliferation and migration of human aortic smooth muscle cells (HASMCs). As shown by our results, MCA inhibited TNF-α-induced cell proliferation by reducing the levels of cyclin D1, cyclin D3, CDK4 and CDK6, and increasing the levels of the cyclin-dependent kinase inhibitors, p21 and p27, without resulting in cellular cytotoxicity. Furthermore, MCA decreased the level of secreted matrix metalloproteinase (MMP)-9 by inhibiting MMP-9 transcription. Unexpectedly, MCA did not affect the TNF-α-induced levels of mitogen-activated protein kinases (MAPKs). However, by showing that MCA potently inhibited the degradation of IkBα and the subsequent nuclear translocation of nuclear factor-κB (NF-κB), we demonstrated that MCA exerts its effects through the NF-κB signaling pathway. MCA also effectively inhibited platelet-derived growth factor (PDGF)-induced HASMC migration. Taken together, these observations suggest that MCA has the potential for use as an anti-atherosclerotic agent.

Introduction

The abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) are major events in the development and progression of atherosclerosis. During the early stages of atherosclerosis, VSMCs migrate from the tunica media into the tunica intima of the arterial wall, and this, along with proliferation, cause intimal thickening and narrowing of the arterial space (1).

Atherogenic lesions are characterized by the accumulation of inflammatory cells and released cytokines (2). Tumor necrosis factor-α (TNF-α) is a major inflammatory cytokine that plays an important role in the initiation and development of atherosclerosis (3). TNF-α is secreted by activated macrophages in atherosclerotic lesions and by VSMCs in the neointima following balloon injury; this cytokine induces the proliferation and migration of VSMCs (4-6). For VSMC migration to occur, the proteolytic degradation or remodeling of the extracellular matrix (ECM) is required. Matrix metalloproteinases (MMPs) are a family of endopeptidases that degrade ECM components, including type IV collagen, laminin and elastin (7,8). Among the MMPs, MMP-9 plays a critical role in VSMC migration and neointima formation, and TNF-α is known to induce VSMC migration via the induction of MMP-9 expression (9,10). As previously demonstrated in an animal model of restenosis, MMP-9-deficient mice exhibit reduced neointima formation due to a defect in VSMC migration, suggesting an important role for MMP-9 in the progression of atherosclerosis (11). TNF-α also induces the expression of cellular adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), and recruits monocytes to injury sites, thereby enhancing the interaction between VSMCs and monocytes at inflammatory sites. This process also plays an important role in the development and progression of atherosclerosis (12). Therefore, the inhibition of TNF-α-mediated VSMC proliferation and migration is considered an important therapeutic strategy for atherosclerosis.

Cinnamon is a widely used food spice that is obtained from the inner bark of Cinnamomum cassia. Cinnamaldehyde, an active component of cinnamon, exhibits various biological functions, such as anti-bacterial, anti-fungal, anti-inflammatory and antitumor activities (13-16). Specifically, the natural derivative, 2-hydroxycinnamaldehyde (HCA), and the synthetic derivative, 2-benzoyloxycinnamaldehyde (BCA), have been shown to effectively induce cell cycle arrest and the subsequent apoptosis of various human cancer cells, including those...
from breast, colon, leukemia, lung and oral cancers (16-19). Recently, we demonstrated that HCA induced the activation of the cell death pathway in a p53-independent manner and that autophagy was actively involved in the HCA-induced apoptosis of oral cancer cells (20). To date, the majority of studies evaluating cinnamaldehyde have focused on its antitumor activity. However, Liao et al demonstrated that cinnamaldehyde inhibited the adhesion of TNF-α-induced monocytes to endothelial cells by suppressing the expression of the cell adhesion molecules, VCAM-1 and ICAM-1 (21). Furthermore, we recently demonstrated that BCA inhibited LPS-induced inducible nitric oxide (NO) synthase (iNOS) expression and subsequent NO production in vitro and in vivo (15). These data demonstrate the anti-inflammatory effects of cinnamaldehyde and suggest that cinnamaldehyde and its derivatives may be possible candidates for use in the treatment of inflammation-related diseases.

In the present study, we evaluated 2-methoxyccinnamaldehyde (MCA), a natural cinnamaldehyde derivative, to determine whether it would be useful as an anti-atherosclerotic agent. Specifically, we evaluated the effects of MCA on the proliferation and migration of human aortic smooth muscle cells (HASMCs) that were exposed to TNF-α. The molecular mechanisms of action of MCA as an anti-atherosclerotic agent were also assessed. To the best of our knowledge, our data provide initial evidence that MCA is a novel candidate for the treatment of atherosclerosis.

**Materials and methods**

**Materials.** The HASMCs and smooth muscle cell medium (SMCM) were purchased from ScienCell (Carlsbad, CA, USA). Recombinant human TNF-α was purchased from R&D Systems (Minneapolis, MN, USA). The antibodies against cyclin D1 (#2926), cyclin D3 (#2936), cyclin-dependent kinase (CDK)4 (#2906), CDK6 (#3136), p15 (#4822), p21 (#2946), p27 (#2552), p65 (#4764), phosphorilated (p-)p65 (#3033), IκBα (#4814), e-Jun N-terminal kinase (JNK; #9225), p-JNK (#4668), p38 (#9212), p-ERK (#4211), extracellular signal-regulated kinase (ERK; #4237) and p-Erk (#370) were obtained from Cell Signaling Technology (Danvers, MA, USA) and the antibodies against TATA-binding protein (TBP; ab818) were purchased from Abcam (Cambridge, MA, USA). Recombinant human platelet-derived growth factor (PDGF) and antibodies against β-actin (A1978) were purchased from Sigma-Aldrich (St. Louis, MO, USA). HCA and MCA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Unless otherwise mentioned, all other chemicals were obtained from Sigma-Aldrich. The HASMCs and smooth muscle cell line were maintained at 37°C under 5% CO2 in SMCM supplemented with the reagents provided with the medium. The cells were treated with various concentrations (1-50 µM) of MCA or HCA (dissolved in 0.1% DMSO) for the indicated periods of time.

**Cell culture and treatment.** The HASMCs were maintained at 37°C under 5% CO2 in SMCM supplemented with the reagents provided with the medium. The cells were treated with various concentrations of MCA or HCA for 24 h. Cell proliferation was evaluated by MTT assay according to a previously described method (22).

**Western blot analysis.** The HASMCs were exposed to TNF-α (10 ng/ml) alone or together with MCA for 24 h. The cells were washed with phosphate-buffered saline (PBS) and lysed in RIPA buffer (PBS supplemented with 1% NP-40, 0.5% sodium deoxycholate, 1 mM PMSF, 1 µg/ml aprotinin, and 1 mM sodium orthovanadate). The cell lysates were then incubated at 4°C for 30 min, followed by centrifugation at 10,000 x g for 10 min. Alternatively, the cytoplasmic and nuclear fractions were obtained using a subcellular fractionation method that has been described previously (23). The protein samples were resolved by sodium dodecyl sulfate-polyacylamide gel electrophoresis (SDS-PAGE) and then transferred onto PVDF membranes. The blots were blocked and then incubated with primary antibodies. The immunoreactive bands were detected using the Immobilon™ Western chemiluminescent HRP substrate (Millipore, Billerica, MA, USA).

**Semi-quantitative RT-PCR.** The cells were exposed to TNF-α alone or together with various concentrations of MCA for 24 h. Total RNA was isolated using TRIzol® reagent (Invitrogen, Carlsbad, CA, USA), and semi-quantitative RT-PCR was

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequences (5’-3’)</th>
<th>Size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMP-9</td>
<td>F: GGATGGGAAATCAGTCGGCATTCT</td>
<td>478</td>
</tr>
<tr>
<td></td>
<td>R: CACTGTTGCCACTTGTTGCA</td>
<td></td>
</tr>
<tr>
<td>MMP-2</td>
<td>F: CTTCCAAGTCTGGAGCCGTAGTA</td>
<td>209</td>
</tr>
<tr>
<td></td>
<td>R: TCTCCAAAGTTCCATACTGCTA</td>
<td></td>
</tr>
<tr>
<td>TIMP1</td>
<td>F: GCTGACCATCGGTTCTGTCAC</td>
<td>272</td>
</tr>
<tr>
<td></td>
<td>R: CAAGCAATGTTGGCCACTCTG</td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>F: CCAAAGTCTCATCCATGACAACTTTG</td>
<td>464</td>
</tr>
<tr>
<td></td>
<td>R: GTACAACAGAAATGAGCGTTGACA</td>
<td></td>
</tr>
</tbody>
</table>

MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinases; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
conducted using the One-Step RT-PCR PreMix kit (Intron Biotechnology, Seongnam, Korea) according to the manufacturer's instructions. The specific primers used for RT-PCR are shown in Table I. RT-PCR was performed under the following conditions: 1 cycle of 30 min at 45˚C, 1 cycle of 5 min at 94˚C, and 25 to 30 cycles of 30 sec at 94˚C, 30 sec at 55˚C, and 40 sec at 72˚C, with a final extension at 72˚C for 5 min. The PCR products were electrophoresed on a 1.7% agarose gel and visualized by ethidium bromide staining.

**Gelatin zymography.** The cell culture supernatants were resuspended in sample buffer (60 mM Tris-Cl, pH 6.8, 15% glycerol, 2% SDS and 0.001% bromophenol blue) and loaded, without boiling, onto a 0.1% gelatin gel containing 10% acrylamide. Following electrophoresis, the gels were washed twice with 0.25% Triton X-100 solution for 30 min/wash and then incubated in incubation buffer (50 mM Tris-Cl, pH 7.6, 5 mM CaCl$_2$, 20 mM NaCl) at 37˚C for 18-24 h to allow for proteolysis of the gelatin. The gels were stained with Coomassie Brilliant Blue R. Proteolysis can be detected as a white zone in a dark blue field.

**Luciferase reporter gene assay.** A 0.71 kb segment at the 5'-flanking region of the human MMP-9 gene, corresponding to GenBank® accession number D10051 was amplified by PCR using genomic DNA from 293 cells (American Type Culture Collection, Manassas, VA, USA) as a template. The luciferase reporter vector for the MMP-9 promoter was created by inserting the MMP-9 promoter DNA fragment into the 5’ SacI and 3’ HindIII sites of the pGL3-Basic vector. The constructs were confirmed by DNA sequencing. To assess the effects of MCA on MMP-9 promoter activity, the cells were co-transfected with pGL3-MMP-9-Luc and pCH110 using the Neon Transfection system (Invitrogen) according to the manufacturer's instructions. After 30 h, the cells were exposed to TNF-α and/or various concentrations of MCA for 24 h. The cells were then lysed and luciferase activity was measured using the Luciferase assay system (Promega). The luciferase activity was normalized to the β-galactosidase activity.

**Immunofluorescence microscopy.** The HASMCs were seeded at a density of 1.5x10$^5$ cells/ml. The cells were cultured overnight and exposed to TNF-α and/or MCA for 3 h. The cells were washed twice with PBS and fixed with 4% paraformaldehyde for 10 min. After being washed twice with PBS, the cells were incubated with methanol for 2 min. The immunostaining was performed as previously described (24). The fluorescence analysis was performed by conventional fluorescence microscopy (Axio Observer D1; Carl Zeiss, Oberkochen, Germany).

**Cell migration assay.** Cell migration assay was performed using the Transwell® system (Corning Inc., Corning, NY, USA). Briefly, the cells were seeded at a density of 3x10$^5$ cells/100 µl on a 0.1% gelatin-coated upper chamber. A 500 µl aliquot of serum-free SMCM with hPDGF (10 ng/ml) and/or MCA was added to the lower compartment of the invasion chamber. Following 24 h of incubation, the filter insert within the upper chamber was removed. The cells on the upper side of the filter were removed using cotton swabs, and the cells that had migrated to the underside of the filter were stained with hematoxylin and eosin (H&E). The migrated cells were observed under a light microscope (Olympus CKX41; Olympus, Tokyo, Japan).

**Statistical analysis.** All experiments were performed at least 3 times and the data are expressed as the means ± SD. ANOVA and the Student's t-test were applied to determine the statistical significance. P-values <0.01 were considered to indicate statistically significant differences.

**Results**

**Effect of MCA on HASMC proliferation and cytotoxicity.** In an effort to find possible anti-atherosclerotic agents, we first evaluated the effects of MCA and HCA, natural derivatives of cinnamaldehyde, on HASMC proliferation (25). Instead of a hydrogen, HCA has a hydroxy group and MCA has a methoxy group at the 2’ site of cinnamaldehyde (Fig. 1). We, as well as others have demonstrated that HCA markedly inhibits the proliferation and induces the apoptosis of various human cancer cells (16,18-20). Consistent with these studies, in this study, HCA significantly decreased cell proliferation in a dose-dependent manner. Treatment with 50 µM HCA reduced cell proliferation by 62.7% compared with the untreated control cells (Fig. 2A). Furthermore, HCA markedly increased cytotoxicity in a dose-dependent manner at a concentration of up to

\[ \text{2-Hydroxycinnamaldehyde (HCA)} \]
\[ \text{2-Methoxycinnamaldehyde (MCA)} \]

Figure 1. Chemical structure of 2-hydroxycinnamaldehyde (HCA) and 2-methoxycinnamaldehyde (MCA).
JIN and KIM: MCA INHIBITS THE TNF-α-INDUCED PROLIFERATION AND MIGRATION OF HASMCs

30 µM (Fig. 2B). We could not obtain reasonable cytotoxicity data for concentrations >50 µM as HCA was highly toxic. On the other hand, MCA only slightly decreased cell proliferation, by 13.3%, at a concentration of 50 µM and did not result in any cytotoxicity up to a concentration of 50 µM (Fig. 2B). Therefore, we used MCA for the subsequent experiments.

**MCA inhibits TNF-α-induced HASMC proliferation.** We then assessed the effects of MCA on TNF-α-induced cell proliferation. The HASMCs were exposed to 10 ng/ml TNF-α alone or together with 50 µM MCA for the indicated periods of time, and cell proliferation was monitored by MTT assay. TNF-α increased cell proliferation by approximately 19.2% at day 3 compared with the untreated control cells, while MCA decreased cell proliferation by approximately 31.1% (Fig. 3A). More importantly, MCA completely abolished the TNF-α-induced increase in HASMC proliferation (Fig. 3A). To confirm the inhibitory effects of MCA on TNF-α-induced cell proliferation, we then examined the expression levels of cell cycle regulatory proteins. The cells were exposed to TNF-α alone or with a combination of various concentrations of MCA for 24 h. TNF-α increased the levels of cyclin D1 and cyclin D3 and markedly increased the levels of CDK6 (Fig. 3B). Of note, MCA attenuated the TNF-α-induced increase in the levels of cyclin D1, cyclin D3 and CDK6 in a dose-dependent manner compared with the control levels of these proteins. Additionally, the levels of the CDK inhibitor (CDKI) proteins, p21 and p27, were increased by MCA. These results suggest that MCA effectively suppresses TNF-α-induced cell proliferation through the regulation of cell cycle regulatory proteins.

**MCA inhibits the TNF-α-induced increase in MMP-9 expression.** MMP-9 plays an important role in VSMC proliferation and migration, and the expression of MMP-9 can be induced by TNF-α (9,10). Thus, to assess whether MCA affects TNF-α-induced MMP-9 expression, a gelatin zymography assay was performed. While no MMP-9 activity was detected in the medium from the untreated control cells, exposure to TNF-α markedly enhanced the secretion of MMP-9, and MCA significantly inhibited the secretion of MMP-9 in a dose-dependent manner (Fig. 4A). Unlike MMP-9, MMP-2 exhibited high proteolytic activity in the medium from the untreated control
cells. Although TNF-α did not affect the level of MMP-2, MCA slightly reduced the level of MMP-2. Compared with the TNF-α-exposed controls, MCA inhibited MMP-9 and MMP-2 secretion by approximately 91.5 and 48.8%, respectively (Fig. 4A).

We then examined whether the MCA-dependent decrease in MMP-9 secretion is caused by the transcriptional regulation of the MMP-9 gene. The cells were exposed to TNF-α alone or together with various concentrations of MCA for 24 h. Total RNA was isolated, and semi-quantitative RT-PCR was performed. Consistent with the results from zymography assay, TNF-α markedly increased the mRNA level of MMP-9, and the TNF-α-induced increase in the MMP-9 mRNA levels was attenuated by MCA in a dose-dependent manner, with a 78.7% inhibition observed in the cells treated with MCA (Fig. 4B).

To further confirm the transcriptional regulation of MMP-9 by MCA, a luciferase reporter gene assay was performed. The cells were transfected with the pGL3-MMP-9-Luc reporter vector and then exposed to TNF-α alone or together with the indicated concentrations of MCA for 24 h. The total cell extracts were subjected to the luciferase assay. Luciferase activities were normalized by co-transfection with a β-galactosidase-expressing vector, pCH110. The data are expressed as the means ± SD of 3 individual experiments. *P<0.01 compared with TNF-α-treated control cells.

Figure 4. 2-Methoxycinnamaldehyde (MCA) inhibits the tumor necrosis factor-α (TNF-α)-induced increase in matrix metalloproteinase-9 (MMP-9) expression in human aortic smooth muscle cells (HASMCs). (A) The cells were exposed to TNF-α alone or together with various concentrations of MCA for 24 h. Gelatin zymography analyses for MMP-9 and MMP-2 were performed using the cell culture supernatants. (B) The cells were exposed to TNF-α alone or together with the indicated concentrations of MCA for 24 h. Total RNA was isolated, and semi-quantitative RT-PCR was performed using the specific primers listed in Table I. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. (C) The cells were transfected with the pGL3-MMP-9-Luc reporter vector. After 30 h, the cells were exposed to TNF-α alone or together with the indicated concentrations of MCA for 24 h. The total cell extracts were subjected to the luciferase assay. Luciferase activities were normalized by co-transfection with a β-galactosidase-expressing vector, pCH110. The data are expressed as the means ± SD of 3 individual experiments. *P<0.01 compared with TNF-α-treated control cells.
an important indicator of its activation, we evaluated whether MCA affects NF-κB subcellular translocation. For this experiment, the HASMCs were exposed to TNF-α and/or MCA for 24 h. The nuclear proteins were separated from the cytosolic proteins through fractionation, and the distribution of NF-κB was evaluated. As expected, TNF-α markedly enhanced the nuclear localization of the NF-κB p65 subunit. However, MCA significantly inhibited the TNF-α-induced nuclear localization of p65. We also demonstrated that the TNF-α-induced nuclear p65 was phosphorylated, which is required for NF-κB activation (Fig. 6A). It is well known that the nuclear translocation of p65 is caused by the degradation of IκBα. Thus, to confirm the effects of MCA on the activation of NF-κB, the levels of IκBα were evaluated. Exposure to TNF-α decreased the level of IκBα compared with the untreated controls (Fig. 6B). However, MCA effectively inhibited the TNF-α-induced IκBα degradation. The effects of MCA on NF-κB activation were also assessed by immunofluorescence staining. Under the control conditions, NF-κB was mainly localized in the cytoplasm, and exposure to TNF-α induced the nuclear translocation of NF-κB. However, co-treatment with MCA and TNF-α resulted in the cytoplasmic localization of NF-κB, suggesting that MCA inhibits the TNF-α-induced NF-κB translocation (Fig. 6C).

MCA inhibits cytokine-induced HASMC migration. Our results demonstrated that MCA effectively inhibited the TNF-α-induced HASMC proliferation and migration by inhibiting the activation of the NF-κB signaling pathway. To further evaluate the potential of MCA as an anti-atherosclerotic agent, a migration assay was performed. For this experiment, HASMC migration was induced by treating the cells with PDGF. PDGF is the strongest chemoattractant that contributes to the progression of atherosclerosis by inducing the proliferation and migration of VSMCs (2,26). Treatment with PDGF (10 ng/ml) markedly enhanced HASMC migration (Fig. 7). However, combined treatment with PDGF and MCA significantly inhibited the PDGF-induced cell migration, suggesting that MCA may be a potential therapeutic agent for atherosclerosis. The TNF-α-induced cell migration was also effectively inhibited by MCA (data not shown).

Discussion

Researches evaluating the pharmacological properties of cinnamaldehyde and its derivatives have focused on its antitumor activity. Among the known natural constituents isolated from *Cinnamomum cassia*, HCA is the most widely studied due to its antitumor activity (16,18-20). However, MCA, another constituent of *Cinnamomum cassia*, has not attracted researchers' interest due to its moderate cytotoxic effects on cancer cells.

The proliferation and migration of VSMCs are critical events in the development of atherosclerotic lesions and cytokines, such as TNF-α and PDGF, are intimately involved in regulating these processes (4-6,26). The first response upon vascular injury is increased SMC proliferation, which continues for 1 to 3 days following injury. In the second phase of lesion development, SMCs migrate from the internal lamina to the intima, usually beginning at day 3 (1,2,4). In this study, we evaluated the anti-atherosclerotic effects of MCA on HASMCs. As expected, HCA exhibited strong cytotoxicity, while MCA did not result in any cytotoxicity up to a concentration of 50 µM (Fig. 2B). Even 100 µM MCA did not result in any cytotoxicity (data not shown). Furthermore, MCA effectively inhibited the TNF-α-induced HASMC proliferation, primarily by decreasing the levels of cyclin D1/CDK6 and inducing the expression of the CDKIs, p21 and p27 (Fig. 3). These results suggest that MCA may be a suitable candidate for the treatment of atherosclerosis.

MMPs play an important role in ECM degradation and remodeling. Among them, MMP-9 and MMP-2 actively contribute to the pathogenesis of atherosclerosis by facilitating the migration of smooth muscle cells into the intima (11,27,28). Furthermore, experiments with knock-out mice showed that MMP-9 is critical for the development of arterial lesions due to its role in regulating VSMC migration and proliferation (11,28,29). Although MMP-9 and MMP-2 have similar substrate specificities, their expression patterns are differentially regulated. MMP-2 is constitutively expressed in smooth muscle cells, and its expression is not affected by cytokines. By contrast, the basal level of MMP-9 is very low, and its expression can be induced by TNF-α (30,31). In this study, the effects of MCA on TNF-α-induced MMP-9 expression were assessed, and the data demonstrated that MCA significantly inhibited TNF-α-induced MMP-9 secretion via the suppression of MMP-9 transcription (Fig. 4). Although the effect was small, MCA also inhibited the constitutive expression of MMP-2 at the transcriptional level.

Previous studies have reported that the induction of MMP-9 expression by TNF-α is regulated by the ERK and JNK signaling pathways, and by the subsequent activation of NF-κB and activator protein 1 (AP-1) in VSMCs (32-34). To understand the precise molecular mechanisms of action for MCA, MAPK activity was examined. Consistent with previous studies, the levels of p-JNK and p-ERK1/2 were elevated by exposure to TNF-α. However, treatment with MCA did not affect the levels of phosphorylated MAPKs, suggesting that MCA inhibits MMP-9 expression through a different signaling pathway.
Figure 6. 2-Methoxycinnamaldehyde (MCA) inhibits tumor necrosis factor-α (TNF-α)-induced nuclear factor-κB (NF-κB) activation. The human aortic smooth muscle cells (HASMCs) were exposed to TNF-α and/or MCA for 24 h. (A) The nuclear fractions were prepared, and the levels of p65 and p-p65 were detected by western blot analysis. (B) The total cell lysates were prepared, and the levels of IκBα were detected by western blot analysis. The band densities were quantified by densitometry. The data are expressed as the means ± SD of the 3 independent experiments. *p<0.01 compared with control cells and **p<0.01 compared with TNF-α-exposed cells. (C) The cells were exposed to TNF-α and/or MCA for 3 h. The localization of NF-κB was detected by immunostaining with anti-p65 antibody and a FITC-conjugated secondary antibody. The nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI).

Figure 7. 2-Methoxycinnamaldehyde (MCA) inhibits platelet-derived growth factor (PDGF)-induced human aortic smooth muscle cells (HASMCs) migration. The migration assay was performed by treating the HASMCs with 10 ng of PDGF and/or 50 µM MCA for 24 h. The migrated cells were stained with H&E and counted under a light microscope. The data are expressed as the means ± SD of 3 independent experiments. *p<0.01 compared with control cells and **p<0.01 compared with PDGF-treated cells.
pathway (Fig. 5). Furthermore, our data clearly demonstrated that MCA inhibited the TNF-α-induced increase in MMP-9 expression through the inhibition of IkBα degradation and, therefore, of subsequent NF-κB activation (Fig. 6).

PDGF is a well-known mitogen and chemoattractant for VSMCs. Similar to TNF-α, PDGF potently stimulates VSMC proliferation and migration and plays an important role in the development of atherosclerosis (2,26). To confirm the anti-atherosclerotic effects of MCA, we also examined the effect of MCA on PDGF-induced HASMC migration; the data clearly demonstrated that MCA potently inhibited, not only TNF-α- (data not shown), but also PDGF-induced cell migration (Fig. 7).

In this study, we demonstrated that MCA effectively inhibited TNF-α-induced HASMC proliferation by reducing the levels of cyclin D1/CDK6 and increasing the levels of the CDKIs, p21 and p27. Furthermore, we demonstrated that MCA potently inhibited the TNF-α-induced increase in MMP-9 expression at the transcriptional level by inhibiting the nuclear translocation of NF-κB via a MAPK-independent signaling pathway. To the best of our knowledge, this is the first study showing that MCA, a natural constituent of Cinnamomum cassia, effectively inhibits TNF-α-induced HASMC proliferation and migration, and this study suggests that MCA may be a potential candidate for the treatment of atherosclerosis.

Acknowledgements

The present study was supported by the MRC program of MOST/KOSEF (no. R13-2005-013-01000-0).

References